Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories

Scandinavian Journal of Immunology

Volumn 86, Issue 3, 2017, Pages 165-170

  Bader, L I ^a,b   Solberg, S M ^a,b   Kaada, S H ^a   Bolstad, N ^c   Warren, D J ^c   Gavasso, S ^a,b   Gjesdal, C G ^a,b   Vedeler, C A ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; BLOOD; COMPARATIVE STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROIMMUNOASSAY; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; REPORTER GENE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROIMMUNOASSAY; GENES, REPORTER; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PATHOLOGY, MOLECULAR; PRECISION MEDICINE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 85027678457     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12572     Document Type: Article

References (22)

1. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443–53.
2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79.
3. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 2015;165:270–82.
4. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601–8.
5. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;5 (Suppl1):19–22.
6. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125–7.
7. Schaeverbeke T, Truchetet ME, Kostine M, Barnetche T, Bannwarth B, Richez C. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford) 2016;55:210–20.
8. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Discov Med 2013;15:201–11.
9. Krieckaert CL, Nair SC, Nurmohamed MT et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361–8.
10. Lazar-Molnar E, Delgado JC. Immunogenicity assessment of tumor necrosis factor antagonists in the clinical laboratory. Clin Chem 2016;62:1186–98.
11. Steenholdt C, Brynskov J, Thomsen OO et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919–27.
12. Thomas SS, Borazan N, Barroso N et al. Comparative Immunogenicity of TNF Inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015;29:241–58.
13. Steenholdt C, Ainsworth MA, Tovey M et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit 2013;35:530–8.
14. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055–64.
15. Vande Casteele N, Buurman DJ, Sturkenboom MG et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765–71.
16. Lallemand C, Kavrochorianou N, Steenholdt C et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods 2011;373:229–39.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.
18. Mulleman D, Chu Miow Lin D, Ducourau E et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010;32:232–6.
19. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029–35.
20. Bloem K, van Leeuwen A, Verbeek G et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015;418:29–38.
21. Jani M, Chinoy H, Warren RB et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet 2015;385 (Suppl 1):S48.
22. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680–6.